The deal for Prometheus is expected to close in the third quarter Terry Lane is a writer for Investopedia with 25 years of experience in journalism and communications. He covers personal finance, ...
Merck announced Sunday morning that it is purchasing Prometheus Biosciences for nearly $11 billion. As part of the definitive agreement, Merck will acquire Prometheus’ lead candidate, PRA023, an anti ...
Merck & Co. announced that it will acquire the immunology company, Prometheus Biosciences, which specializes in inflammatory bowel disease (IBD) treatments. Under the terms of the deal, Merck will ...
- PRA052 is the second clinical candidate identified using the Prometheus360™ platform with one of the strongest genetic associations to IBD and is linked to a broad range of immune-mediated diseases ...
SAN DIEGO, May 09, 2023 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (RXDX) (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback